Trial | NCT00471211  Report issue

Title

Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients With Early Alzheimer's Disease
A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel Three-Group Study to Assess the Safety, Tolerability and Efficacy of Two Dose Levels of PBT2 to Slow Progression of Disease in Patients With Early Alzheimer's Disease

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    pbt2 ...

  • Study Participants

    80
The purpose of the study is to determine the safety, tolerability and efficacy of 2 doses of PBT2 administered for 12 weeks compared to placebo in patients with early Alzheimer's disease treated with an acetylcholinesterase inhibitor.
Study Started
Dec 31
2006
Primary Completion
Dec 31
2007
Study Completion
Dec 31
2007
Last Update
Jan 16
2008
Estimate

Drug PBT2

Criteria 

Inclusion Criteria:

diagnosis of probable early Alzheimer's disease
stable dose of acetylcholinesterase inhibitor
community dwelling
stable medical condition

Exclusion Criteria:

unstable and significant medical conditions
recurrent major psychiatric disorder
treatment with memantine
No Results Posted